Mangalam Drugs And Organics Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mangalam Drugs has submitted a compliance certificate for Q4 FY2025-26 (January 01, 2026 to March 31, 2026) as required under SEBI regulations. The certificate from Registrar MUFG Intime India confirms that all securities received for dematerialisation during the quarter were properly processed - accepted/rejected and confirmed to depositories. The certificate also confirms that physical security certificates received were mutilated and cancelled after due verification, and depository names were substituted in the register of members within the prescribed timelines. This is a routine regulatory filing confirming proper handling of dematerialisation requests.
This is a standard compliance filing with no direct impact on company financials or operations. It simply confirms the company followed proper SEBI-mandated procedures for share dematerialisation during the quarter. No material impact on shareholders or stock price.